At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 110 enrolled
Drug / intervention
Risankizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Extension Trial Assessing the Safety and Efficacy of BI 655066/ ABBV-066/Risankizumab Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating Risankizumab for Psoriasis. Completed, enrolled 110 participants.
Detailed Summary
The primary objective of Study M16-009 was to investigate the safety of risankizumab in participants with moderate to severe chronic plaque psoriasis who were receiving long-term treatment. Additional study objectives were to further investigate the long-term efficacy, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of risankizumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
CollaboratorsBoehringer Ingelheim
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartNov 2014
Primary CompletionSep 2018
TodayJul 2026
First PostedJul 30, 2014
Enrollment StartNov 20, 2014
Primary CompletionSep 4, 2018
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 11.9 years ago
Interventions
Risankizumabdrug
Risankizumab administered by subcutaneous (SC) injection